Evolent Q3 Revenue Jumps 51% to $725M but Net Loss Widens to $23.6M
EVH has more than doubled off its 52-week low of $2.095.
Summary
Evolent grew Q3 revenue 51% to $725.4 million on new Performance Suite contracts, but a 93.0% medical expense ratio pushed it to a $23.6 million net loss. Amended credit agreements now permit up to $50 million of 2029 convertible note repurchases.
Key Events · Earnings and Guidance · EVH
-
Q3 Revenue Up 51% to $725.4M
Revenue rose $245.8 million, or 51.3%, to $725.4 million, driven by $280.1 million of new Performance Suite contract go-lives and expanded oncology services, partly offset by $22.3 million of membership reductions.
-
Net Loss Widens to $23.6M
Net loss attributable to common shareholders was $23.6 million, or $0.21 per share, versus $26.9 million a year earlier; operating result swung to a $6.2 million loss from $0.9 million of income.
-
Medical Expense Ratio Climbs to 93.0%
MER rose from 85.0% to 93.0% as claims incurred on the specialty care management solution reached $525.0 million against $564.3 million of Performance Suite revenue; cost of revenue grew 67.7%, faster than revenue.
-
Credit Agreements Amended October 15
Amendment No. 7 to the First Lien Credit Agreement and Amendment No. 1 to the Second Lien Credit Agreement expand restricted-payment baskets, including repurchases of up to $50 million of 2029 convertible notes through October 15, 2027, funded solely from internally generated cash.
Analysis · EVH · Trade & Services
Revenue growth is real — $280.1 million of new Performance Suite contract go-lives and expanded oncology services drove the 51.3% jump — but the economics are getting thinner, not better. The Medical Expense Ratio climbed to 93.0% from 85.0%, meaning claims costs are eating a larger share of Performance Suite revenue, and cost of revenue rose 67.7% against 51.3% revenue growth. The result is a $6.2 million operating loss versus a small operating profit a year ago. Cash slipped to $148.3 million from $151.9 million at year-end while the claims reserve nearly doubled to $376.1 million, so the balance sheet is carrying more medical-cost risk. Management still says liquidity covers the next twelve months, and the newly amended credit agreements free up capacity to repurchase up to $50 million of the 2029 convertible notes with internally generated cash — a signal they intend to chip away at the $569.3 million convertible stack rather than raise equity.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVH was trading at $4.56 on NYSE in the Trade & Services sector, with a market capitalization of approximately $542.7M. The 52-week trading range was $2.10 to $6.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.